Curated news and analysis on clinical trials, drug approvals, and medical research.
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
Engineered regulatory T cell therapies are progressing through clinical trials for autoimmune diseases and organ transplant rejection, with CAR-Treg candidates showing promising early results in rheumatoid arthritis and other conditions.
The FDA has approved labeling changes to six menopausal hormone therapy products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia that had been in place since 2003.
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
Eli Lilly has accumulated $1.5 billion in pre-launch inventory of its experimental oral weight-loss drug orforglipron ahead of an expected FDA decision in April, up from $550 million last year.
Innovent Biologics has dosed the first participant in its pivotal Phase 3 HeriCare-Breast01 study evaluating IBI354, a HER2-targeted antibody-drug conjugate, as first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer.
China now leads globally with 624 Phase 3 cancer trials, representing 48.5% of the total, while its share of global drug development has risen to 20% with investigational new drugs accounting for 30% of the world's pipeline.
WHO has granted Phase II pre-qualification for Biological E Limited's novel Oral Polio Vaccine type 2, enabling full end-to-end manufacturing at a single integrated site in Hyderabad.
Ultragenyx reported Q4 2025 revenues of $207 million, up 25% year-over-year, while announcing a 10% workforce reduction and resubmission of its UX111 gene therapy application following positive long-term clinical data.
Emergent BioSolutions received FDA approval on Feb. 12, 2026, for 6-count and 24-count multipack configurations of over-the-counter NARCAN Nasal Spray, designed to meet the needs of partners distributing higher volumes of naloxone to community programs.
Samsung Bioepis and Regeneron reached a settlement allowing U.S. launch of Opuviz, an aflibercept biosimilar, in January 2027. The agreement resolves a patent dispute that began in late 2023.
The FDA mandated febrile seizure warnings for flu vaccines and rejected Moderna's mRNA flu vaccine application, with a political appointee overruling agency staff despite no safety concerns identified.
An international research team has identified antibody 007, which targets HIV-1's V3 glycan site without depending on sugar structures the virus frequently alters, remaining effective against resistant variants and enhancing combination therapies.
AAV-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment for neovascular AMD, with leading clinical candidates including RGX-314, ADVM-022, 4D-150, and NG101.
Vertex Pharmaceuticals reported fourth quarter 2025 revenue of $3.19 billion, up 10% year-over-year, and provided full year 2026 revenue guidance of $12.95 billion to $13.1 billion with over $500 million expected from non-CF products.
Vistagen reported fiscal Q3 2026 results with $61.8 million in cash as of December 31, 2025, while advancing its PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder and preparing an IND submission for refisolone in menopause symptoms.
Bio-Rad Laboratories reported Q4 2025 revenue of $693.2 million, up 3.9%, driven by Clinical Diagnostics growth, while Life Science sales declined 2.6% due to constrained academic and biotech funding. Gross and operating margins fell below expectations.
MoonLake Immunotherapeutics announced positive topline results from its Phase 2 S-OLARIS trial of sonelokimab in axial spondyloarthritis, with 81% of patients achieving ASAS40 response by Week 12. The company ended Q4 2025 with $394 million in cash.
California-based Centivax has begun dosing participants in a Phase 1A clinical trial of Centi-Flu 01, a universal influenza vaccine designed to target conserved viral regions across all flu strains. Initial data from approximately 180 participants is expected within the year.
Multiple law firms have filed securities class actions against Inovio Pharmaceuticals after the FDA accepted its INO-3107 BLA for standard rather than accelerated review, following earlier manufacturing delays with the CELLECTRA device.
